BioSpace News Archive

Parthenon Therapeutics today announced that the first patient has been dosed with PRTH-101 in a Phase 1, first-in-human clinical trial for patients with immune-excluded solid tumors.

908 Devices Inc. today announced it will report financial results for the first quarter 2023 before market open on Tuesday, May 9, 2023.

Rectify Pharmaceuticals, Inc. today announced the appointment of Sachiyo Minegishi as Chief Operating Officer.

Elucid, Inc today announced that it has named Scott Huennekens executive chairman of its board of directors.

SOPHiA GENETICS today announced it will release its financial results for the first quarter of fiscal 2023 before U.S. markets open on Tuesday, May 9, 2023.

Albatroz Therapeutics today announced it has secured $3 million USD in funding led by Outram Bio and SEEDS Capital to accelerate the development of therapeutic antibodies against a novel target that degrades the extracellular matrix, a key contributor to cancer and arthritis.

Orthofix Medical Inc today announced the full commercial launch of two access retractor systems to aid surgeons during minimally invasive spine (MIS) procedures.

Bausch + Lomb Corporation today announced the election of the 10 directors nominated at its 2023 annual meeting of shareholders (the “Annual Meeting”) held on April 24, 2023.

CureVac N.V. (Nasdaq:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the fourth quarter and full-year 2022 and provided a business update.

Anavex Life Sciences Corp. today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference at NASDAQ being held May 2nd, 2023 at 9:30am ET at NASDAQ World Headquarters New York City.